Completed NA INTERVENTIONAL 2-arm NCT00551343

Gut Derived Hormones, Body Composition and Metabolism in Prader-Willi Syndrome

Contribution of a GLP-1 Agonist to Appetite Regulation, Metabolism and Body Composition in Subjects With Prader-Willi Syndrome.

Sponsor: Garvan Institute of Medical Research

Conditions Prader-Willi Syndrome

Interventions Exenatide

Updated 5 times since 2017 Last updated: Jul 3, 2020 Started: Oct 31, 2007 Primary completion: Sep 30, 2008 Completion: Sep 30, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Prader-Willi Syndrome and is currently completed. Garvan Institute of Medical Research leads this study, which shows 5 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Aug 2020 — Jan 2021 [monthly]

Completed NA

Status: Unknown Status → Completed
Jan 2017 — Aug 2020 [monthly]

Unknown Status NA

First recorded

Oct 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Garvan Institute of Medical Research

Data source: Garvan Institute of Medical Research

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Sydney, Australia